Metabolik Sendrom ve Bileşenlerinde Sitokin Yanıtı

Yarim, Gul Fatma; Kazak, Filiz

Metabolik Sendrom ve Bileşenlerinde Sitokin Yanıtı

Gul Fatma Yarim, (Ondokuz Mayıs Üniversitesi, Veteriner Fakültesi, Biyokimya Anabilim Dalı, Samsun, Türkiye.)

Filiz KAZAK (Ondokuz Mayıs Üniversitesi, Veteriner Fakültesi, Biyokimya Anabilim Dalı, Samsun, Türkiye.)

Harran Üniversitesi Veteriner Fakültesi Dergisi

1 0

Yıl: 2016 Cilt: 5 Sayı: 1 Sayfa Aralığı: 90 - 99 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Metabolik Sendrom ve Bileşenlerinde Sitokin Yanıtı

Öz:

Obezite ve diyabet prevalansının artışı ile paralel olarak metabolik sendromun prevalansı da gün geçtikçe artmaktadır. Bozulmuş glukoz toleransı, dislipidemi ve hipertansiyon gibi metabolik sendrom bileşenlerinin düşük dereceli sistemik enflamasyon ile ilişkili olduğu pek çok deneysel ve klinik çalışma ile kanıtlanmıştır. Metabolik sendromda enflamatuar sinyal yolakları aktive olarak, proenflamatuar ve antienflamatuar sitokinlerin salınımı değişmekte ve metabolik sendroma atfedilen biyokimyasal ve klinik bozukluklara yol açmaktadır. Bu derlemenin amacı, metabolik sendromda rol alan sitokinler ve değişiklikleri hakkında bilgi sunmaktır

Anahtar Kelime:

Konular: Endokrinoloji ve Metabolizma Pediatri

Cytokine Response in Metabolic Syndrome and its Components

Öz:

In parallel with the increasing prevalence of obesity and type 2 diabetes, the prevalence of metabolic syndrome increases day by day. The metabolic syndrome components such as impaired glucose tolerance, dyslipidemia and hypertension to be associated with systemic inflammation has been proven by many experimental and clinical studies. In metabolic syndrome, activated inflammatory signaling pathways triggers the release of proinflammatory cytokines which leads to biochemical and clinical abnormalities. The aim of this review is to present current information on the role of cytokines in the metabolic syndrome

Anahtar Kelime:

Konular: Endokrinoloji ve Metabolizma Pediatri

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

Alderson MR, Tough TW, Ziegler SF, Grabstein KH, 1991: Interleukin 7 induces cytokine secretion and tumoricidal activity by human peripheral blood monocytes. J Exp Med, 173(4), 923-930.
Anand G, Vasanthakumar R, Mohan V, Babu S, Aravindhan V, 2014: Increased IL-12 and decreased IL-33 serum levels are associated with increased Th1 and suppressed Th2 cytokine profile in patients with diabetic nephropathy (CURES-134). Int J Clin Exp Pathol, 7(11), 8008-8015.
Bailey SR, Habershon-Butcher JL, Ransom KJ, Elliott J, Menzies-Gow NJ, 2008: Hypertension and insulin resistance in a mixed-breed population of ponies predisposed to laminitis. Am J Vet Res, 69(1), 122- 129.
Bao P, Liu G, Wei Y, 2015: Association between IL-6 and related risk factors of metabolic syndrome and cardiovascular disease in young rats. Int J Clin Exp Med, 8(8), 13491-13499.
Bastien BC, Patil A, Satyaraj E, 2015: The impact of weight loss on circulating cytokines in Beagle dogs. Vet Immunol Immunopathol, 163(3-4), 174-182.
Barksby HE, Lea SR, Preshaw PM, Taylor JJ, 2007: The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders. Clin Exp Immunol, 149(2), 217-225.
Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Bonadonna RC, Muggeo M, Bruneck Study, 2003: Metabolic syndrome: epidemiology and more extensive phenotypic description. Cross-sectional data from the Bruneck Study. Int J Obes Relat Metab Disord, 27(10), 1283-1289.
Brindley DN, Wang CN, Mei J, Xu J, Hanna AN, 1999: Tumor necrosis factor-alpha and ceramides in insulin resistance. Lipids, 34, S85-88.
Bruun JM, Pedersen SB, Richelsen B, 2000: Interleukin-8 production in human adipose tissue. inhibitory effects of anti-diabetic compounds, the thiazolidinedione ciglitazone and the biguanide metformin. Horm Metab Res, 32(11-12), 537-541.
Caltabilota TJ, Earl LR, Thompson DL Jr, Clavier SE, Mitcham PB, 2010: Hyperleptinemia in mares and geldings: assessment of insulin sensitivity from glucose responses to insulin injection. J Anim Sci, 88(9), 2940-2949.
Cartier A, Lemieux I, Alméras N, Tremblay A, Bergeron J, Després JP, 2008: Visceral obesity and plasma glucose-insulin homeostasis: contributions of interleukin-6 and tumor necrosis factor-alpha in men. J Clin Endocrinol Metab, 93(5), 1931-1938.
Chan JC, Cheung JC, Stehouwer CD, Emeis JJ, Tong PC, Ko GT, Yudkin JS, 2002: The central roles of obesityassociated dyslipidaemia, endothelial activation and cytokines in the Metabolic Syndrome--an analysis by structural equation modelling. Int J Obes Relat Metab Disord, 26(7), 994-1008.
Chang JS, Bai CH, Huang ZC, Owaga E, Chao KC, Chang CC, Chiou HY, 2014: Interleukin 10 and clustering of metabolic syndrome components in pediatrics. Eur J Clin Invest, 44(4):384-394.
Charrière G, Cousin B, Arnaud E, André M, Bacou F, Penicaud L, Casteilla L, 2003: Preadipocyte conversion to macrophage. Evidence of plasticity. J Biol Chem, 278(11), 9850-9855.
Chen G, Goeddel DV, 2002: TNF-R1 signaling: a beautiful pathway. Science, 296(5573), 1634-1635.
Chomarat P, Banchereau J, Davoust J, Palucka AK, 2000: IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat Immunol, 1(6), 510-514.
Cousin B, Munoz O , Andre M, Fontanilles AM, Dani C, Cousin JL, Laharrague P, Casteilla L, Pénicaud L, 1999: A role for preadipocytes as macrophage-like cells. FASEB J, 13(2):305-312.
De Alvaro C, Teruel T, Hernandez R, Lorenzo M, 2004: Tumor necrosis factor alpha produces insulin resistance in skeletal muscle by activation of inhibitor kappaB kinase in a p38 MAPK-dependent manner. J Biol Chem, 279(17), 17070-17078.
Del Prete G, De Carli M, Almerigogna F, Giudizi MG, Biagiotti R, Romagnani S, 1993: Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigenspecific proliferation and cytokine production. J Immunol, 150(2), 353-360.
Dinarello CA, 2002: The IL-1 family and inflammatory diseases. Clin Exp Rheumatol, 20(5 Suppl 27), S1-13.
Durpès MC, Morin C, Paquin-Veillet J, Beland R, Paré M, Guimond MO, Rekhter M, King GL, Geraldes P, 2015: PKC-β activation inhibits IL-18-binding protein causing endothelial dysfunction and diabetic atherosclerosis. Cardiovasc Res, 106(2), 303-313.
Edney AT, Smith PM, 1986: Study of obesity in dogs visiting veterinary practices in the United Kingdom. Vet Rec, 118(14), 391-396.
Esposito K, Pontillo A, Giugliano F, Giugliano G, Marfella R, Nicoletti G, Giugliano D, 2003: Association of low interleukin-10 levels with the metabolic syndrome in obese women. J Clin Endocrinol Metab, 88(3), 1055-1058.
Foss-Freitas MC, Foss NT, Donadi EA, Foss MC, 2006: In vitro TNF-alpha and IL-6 production by adherent peripheral blood mononuclear cells obtained from type 1 and type 2 diabetic patients evaluated according to the metabolic control. Ann N Y Acad Sci, 1079, 177-180.
Frank N, Elliott SB, Brandt LE, Keisler DH, 2006: Physical characteristics, blood hormone concentrations, and plasma lipid concentrations in obese horses with insulin resistance. J Am Vet Med Assoc, 228(9), 1383-1390.
German AJ, 2006: The growing problem of obesity in dogs and cats. J Nutr, 136 (7 Suppl), 1940S-1946S.
German AJ, Hervera M, Hunter L, Holden SL, Morris PJ, Biourge V, Trayhurn P, 2009: Improvement in insulin resistance and reduction in plasma inflammatory adipokines after weight loss in obese dogs. Domest Anim Endocrinol, 37(4), 214-226.
Ghanim H, Aljada A, Hofmeyer D, Syed T, Mohanty P, Dandona P, 2004: Circulating mononuclear cells in the obese are in a proinflammatory state. Circulation, 110(12), 1564-1571.
Ginsberg HN, Zhang YL, Hernandez-Ono A, 2006: Metabolic syndrome: focus on dyslipidemia. Obesity, 14(1), 41S-49S.
Gracie JA, Robertson SE, McInnes IB, 2003: Interleukin- 18. J Leukoc Biol, 73(2), 213-224.
Greenberg AS, Nordan RP, McIntosh J, Calvo JC, Scow RO, Jablons D, 1992: Interleukin 6 reduces lipoprotein lipase activity in adipose tissue of mice in vivo and in 3T3-L1 adipocytes: a possible role for interleukin 6 in cancer cachexia. Cancer Res, 52(15), 4113-4116.
Han JM, Wu D, Denroche HC, Yao Y, Verchere CB, Levings MK, 2015: IL-33 Reverses an Obesity-Induced Deficit in Visceral Adipose Tissue ST2+ T Regulatory Cells and Ameliorates Adipose Tissue Inflammation and Insulin Resistance. J Immunol, 194(10), 4777-4783.
Hasan A, Al-Ghimlas F, Warsame S, Al-Hubail A, Ahmad R, Bennakhi A, Al-Arouj M, Behbehani K, Dehbi M, Dermime S, 2014: IL-33 is negatively associated with the BMI and confers a protective lipid/metabolic profile in non-diabetic but not diabetic subjects. BMC Immunol, 15,19.
Hauer AD, Uyttenhove C, de Vos P, Stroobant V, Renauld JC, van Berkel TJ, van Snick J, Kuiper J, 2005: Blockade of interleukin-12 function by protein vaccination attenuates atherosclerosis. Circulation, 112(7), 1054-1062.
He J, Usui I, Ishizuka K, Kanatani Y, Hiratani K, Iwata M, Bukhari A, Haruta T, Sasaoka T, Kobayashi M, 2006: Interleukin-1alpha inhibits insulin signaling with phosphorylating insulin receptor substrate-1 on serine residues in 3T3-L1 adipocytes. Mol Endocrinol, 20(1), 114-124.
Henney CS, 1989: Interleukin 7: effects on early events in lymphopoiesis. Immunol Today, 10(5), 170-173.
Hong EG, Ko HJ, Cho YR, Kim HJ, Ma Z, Yu TY, Friedline RH, Kurt-Jones E, Finberg R, Fischer MA, Granger EL, Norbury CC, Hauschka SD, Philbrick WM, Lee CG, Elias JA, Kim JK, 2009: Interleukin-10 prevents dietinduced insulin resistance by attenuating macrophage and cytokine response in skeletal muscle. Diabetes, 58(11), 2525-2535.
Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM, 1996: IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNFalpha- and obesity-induced insulin resistance. Science, 271(5249), 665-668.
Hotamisligil GS, Shargill NS, Spiegelman BM, 1993: Adipose expression of tumor necrosis factoralpha:direct role in obesity-linked insulin resistance. Science, 259(5091), 87-91.
Hube F, Birgel M, Lee YM, Hauner H, 1999: Expression pattern of tumour necrosis factor receptors in subcutaneous and omental human adipose tissue: role of obesity and non-insulin-dependent diabetes mellitus. Eur J Clin Invest, 29(8), 672-678.
Isakson P, Hammarstedt A, Gustafson B, Smith U, 2009: Impaired preadipocyte differentiation in human abdominal obesity: role of Wnt, tumor necrosis factor-alpha, and inflammation. Diabetes, 58(7), 1550-1557.
Jager J, Grémeaux T, Cormont M, Le Marchand-Brustel Y, Tanti JF, 2007: Interleukin-1beta-induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression. Endocrinology, 148(1), 241-251.
Johnson PJ, 2002: The equine metabolic syndrome peripheral Cushing's syndrome. Vet Clin North Am Equine Pract, 18(2), 271-293.
Jung SH, Park HS, Kim KS, Choi WH, Ahn CW, Kim BT, Kim SM, Lee SY, Ahn SM, Kim YK, Kim HJ, Kim DJ, Lee KW, 2008: Effect of weight loss on some serum cytokines in human obesity: increase in IL-10 after weight loss. J Nutr Biochem, 19(6), 371-375.
Kamari Y, Shaish A, Vax E, Shemesh S, Kandel-Kfir M, Arbel Y, Olteanu S, Barshack I, Dotan S, Voronov E, Dinarello CA, Apte RN, Harats D, 2011: Lack of interleukin-1α or interleukin-1β inhibits transformation of steatosis to steatohepatitis and liver fibrosis in hypercholesterolemic mice. J Hepatol, 55(5), 1086-1094.
Kamari Y, Werman-Venkert R, Shaish A, Werman A, Harari A, Gonen A, Voronov E, Grosskopf I, Sharabi Y, Grossman E, Iwakura Y, Dinarello CA, Apte RN, Harats D, 2007: Differential role and tissue specificity of interleukin-1alpha gene expression in atherogenesis and lipid metabolism. Atherosclerosis, 195(1), 31-38.
Kanety H, Feinstein R, Papa MZ, Hemi R, Karasik A, 1995: Tumor necrosis factor alpha-induced phosphorylation of insulin receptor substrate-1 (IRS- 1). Possible mechanism for suppression of insulinstimulated tyrosine phosphorylation of IRS-1. J Biol Chem, 270(40), 23780-23784.
Kim AY, Kim HS, Kang JH, Yang MP, 2015: Serum adipokine concentrations in dogs with diabetes mellitus: a pilot study. J Vet Sci, 16(3), 333-340.
Kim CS, Park HS, Kawada T, Kim JH, Lim D, Hubbard NE, Kwon BS, Erickson KL, Yu R, 2006: Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters. Int J Obes (Lond), 30(9), 1347-1355.
Lagathu C, Yvan-Charvet L, Bastard JP, Maachi M, Quignard-Boulangé A, Capeau J, Caron M, 2006: Long-term treatment with interleukin-1beta induces insulin resistance in murine and human adipocytes. Diabetologia, 49(9), 2162-2173.
Lee M, Song SJ, Choi MS, Yu R, Park T, 2015a: IL-7 receptor deletion ameliorates diet-induced obesity and insulin resistance in mice. Diabetologia, 58(10), 2361-2370.
Lee TS, Yen HC, Pan CC, Chau LY, 1999: The role of interleukin 12 in the development of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol, 19(3), 734-42.
Lee YH, Kim JH, Song GG, 2015b: Interleukin-18 promoter -607 C/A and -137 G/C polymorphisms and susceptibility to type 1 diabetes: A metaanalysis. Hum Immunol, 76(8), 537-545.
Leon-Cabrera S, Arana-Lechuga Y, Esqueda-León E, Terán-Pérez G, Gonzalez-Chavez A, Escobedo G, Velázquez MJ, 2015: Reduced systemic levels of IL- 10 are associated with the severity of obstructive sleep apnea and insulin resistance in morbidly obese humans. Mediators Inflamm, 2015, 493409.
Li R, Paul A, Ko KW, Sheldon M, Rich BE, Terashima T, Dieker C, Cormier S, Li L, Nour EA, Chan L, Oka K, 2012: Interleukin-7 induces recruitment of monocytes/macrophages to endothelium. Eur Heart J, 33(24), 3114-3123.
Liu LS, Spelleken M, Röhrig K, Hauner H, Eckel J, 1998: Tumor necrosis factor-alpha acutely inhibits insulin signaling in human adipocytes: implication of the p80 tumor necrosis factor receptor. Diabetes, 47(4), 515-522.
Locksley RM, Killeen N, Lenardo MJ, 2001: The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell, 104(4), 487-501.
Lorenzo M, Fernández-Veledo S, Vila-Bedmar R, GarciaGuerra L, De Alvaro C, Nieto-Vazquez I, 2008: Insulin resistance induced by tumor necrosis factor-alpha in myocytes and brown adipocytes. J Anim Sci, 86(14 Suppl), E94-104.
Lucas S, Taront S, Magnan C, Fauconnier L, Delacre M, Macia L, Delanoye A, Verwaerde C, Spriet C, Saule P, Goormachtigh G, Héliot L, Ktorza A, Movassat J, Polakowska R, Auriault C, Poulain-Godefroy O, Di Santo J, Froguel P, Wolowczuk I, 2012: Interleukin-7 regulates adipose tissue mass and insulin sensitivity in high-fat diet-fed mice through lymphocytedependent and independent mechanisms. PLoS One, 7(6), e40351.
Lund EM, Armstrong PJ, Kirk CA, Klausner JS, 2005: Prevalence and risk factors for obesity in adult cats from private US veterinary practices. Int J Appl Res Vet Med, 3, 88-96.
Lund EM, Armstrong PJ, Kirk CA, Klausner JS, 2006: Prevalence and risk factors for obesity in adult dogs from private US veterinary practices. Int J Res Vet Med, 4, 177-186.
Mahmoud RA, el-Ezz SA, Hegazy AS, 2004: Increased serum levels of interleukin-18 in patients with diabetic nephropathy. Ital J Biochem, 53(2), 73-81.
Martinez-Hervas S, Martínez-Barquero V, Nuñez SE, Lendínez V, Olivares L, Benito E, Real JT, Chaves FJ, Ascaso JF, 2015: Plasma IL-18 levels are related to insulin and are modulated by IL-18 gene polymorphisms. Clin Investig Arterioscler, 27(6), 265-271.
Maury E, Ehala-Aleksejev K, Guiot Y, Detry R, Vandenhooft A, Brichard SM, 2007: Adipokines oversecreted by omental adipose tissue in human obesity. Am J Physiol Endocrinol Metab, 293(3), E656-665.
McGillicuddy FC, Chiquoine EH, Hinkle CC, Kim RJ, Shah R, Roche HM, Smyth EM, Reilly MP, 2009: Interferon gamma attenuates insulin signaling, lipid storage, and differentiation in human adipocytes via activation of the JAK/STAT pathway. J Biol Chem, 284(46), 31936-31944.
McInnes IB, Gracie JA, Leung BP, Wei XQ, Liew FY, 2000: Interleukin 18: a pleiotropic participant in chronic inflammation. Immunol Today, 21(7), 312-315.
McLaren JE, Michael DR, Salter RC, Ashlin TG, Calder CJ, Miller AM, Liew FY, Ramji DP, 2010: IL-33 reduces macrophage foam cell formation. J Immunol, 185(2), 1222-1229.
Mehlman E, Bright JM, Jeckel K, Porsche C, Veeramachaneni DN, Frye M, 2013: Echocardiographic evidence of left ventricular hypertrophy in obese dogs. J Vet Intern Med, 27(1), 62-68.
Mehta DS, Wurster AL, Grusby MJ, 2004: Biology of IL-21 and the IL-21 receptor. Immunol Rev, 202, 84-95. Miller AM, 2011: Role of IL-33 in inflammation and disease. J Inflamm (Lond), 8(1), 22.
Miller AM, Asquith DL, Hueber AJ, Anderson LA, Holmes WM, McKenzie AN, Xu D, Sattar N, McInnes IB, Liew FY, 2010: Interleukin-33 induces protective effects in adipose tissue inflammation during obesity in mice. Circ Res, 107(5), 650-658.
Miller AM, Xu D, Asquith DL, Denby L, Li Y, Sattar N, Baker AH, McInnes IB, Liew FY, 2008: IL-33 reduces the development of atherosclerosis. J Exp Med, 205(2), 339-346.
Mirhafez SR, Pasdar A, Avan A, Esmaily H, Moezzi A, Mohebati M, Meshkat Z, Mehrad-Majd H, Eslami S, Rahimi HR, Ghazavi H, Ferns GA, Ghayour-Mobarhan M, 2015: Cytokine and growth factor profiling in patients with the metabolic syndrome. Br J Nutr, 113(12), 1911-1119.
Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW, 1997: Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab, 82(12), 4196-4200.
Moon YS, Kim DH, Song DK, 2004: Serum tumor necrosis factor-alpha levels and components of the metabolic syndrome in obese adolescents. Metabolism, 53(7), 863-867.
Moreau M, Brocheriou I, Petit L, Ninio E, Chapman MJ, Rouis M, 1999: Interleukin-8 mediates downregulation of tissue inhibitor of metalloproteinase-1 expression in cholesterolloaded human macrophages: relevance to stability of atherosclerotic plaque. Circulation, 99(3), 420- 426.
Murphy AJ, Kraakman MJ, Kammoun HL, Dragoljevic D, Lee MK, Lawlor KE, Wentworth JM, Vasanthakumar A, Gerlic M, Whitehead LW, DiRago L, Cengia L, Lane RM, Metcalf D, Vince JE, Harrison LC, Kallies A, Kile BT, Croker BA, Febbraio MA, Masters SL, 2015: IL-18 Production from the NLRP1 Inflammasome Prevents Obesity and Metabolic Syndrome. Cell Metab, 23(1), 155-64.
Nam H, Ferguson BS, Stephens JM, Morrison RF, 2013: Impact of obesity on IL-12 family gene expression in insulin responsive tissues. Biochim Biophys Acta, 1832(1), 11-19.
Nikołajuk A, Karczewska-Kupczewska M, Straczkowski M, 2015: Relationship Between Serum IL-12 and p40 Subunit Concentrations and Lipid Parameters in Overweight and Obese Women. Metab Syndr Relat Disord, 13(8), 336-342.
O'Neill S, Drobatz K, Satyaraj E, Hess R, 2012: Evaluation of cytokines and hormones in dogs before and after treatment of diabetic ketoacidosis and in uncomplicated diabetes mellitus. Vet Immunol Immunopathol, 148(3-4), 276-283.
Opal SM, DePalo VA, 2000: Anti-inflammatory cytokines. Chest, 117(4), 1162-1172.
O'Rourke RW, White AE, Metcalf MD, Winters BR, Diggs BS, Zhu X, Marks DL, 2012: Systemic inflammation and insulin sensitivity in obese IFN-γ knockout mice. Metabolism, 61(8), 1152-1161.
Pacifico L, Di Renzo L, Anania C, Osborn JF, Ippoliti F, Schiavo E, Chiesa C, 2006: Increased T-helper interferon-gamma-secreting cells in obese children. Eur J Endocrinol, 154(5), 691-697.
Pelletier M, Girard D, 2007: Biological functions of interleukin-21 and its role in inflammation. Scientific World Journal, 7, 1715-1735.
Pickup JC, Mattock MB, Chusney GD, Burt D, 1997: NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia, 40(11), 1286-1292.
Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM, 2001: C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA, 286(3), 327-334.
Raymond NC, Dysken M, Bettin K, Eckert ED, Crow SJ, Markus K, Pomeroy C, 2000: Cytokine production in patients with anorexia nervosa, bulimia nervosa, and obesity. Int J Eat Disord, 28(3), 293-302.
Rocha VZ, Folco EJ, Sukhova G, Shimizu K, Gotsman I, Vernon AH, Libby P, 2008: Interferon-gamma, a Th1 cytokine, regulates fat inflammation: a role for adaptive immunity in obesity. Circ Res, 103(5), 467- 476.
Rotter V, Nagaev I, Smith U, 2003: Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulinresistant subjects. J Biol Chem, 278(46), 45777- 45784.
Samad F, Ruf W, 2013: Inflammation, obesity, and thrombosis. Blood, 122(20), 3415-3422. Schoenborn JR, Wilson CB, 2007: Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol, 96, 41-101.
Spolski R, Kashyap M, Robinson C, Yu Z, Leonard WJ, 2008: IL-21 signaling is critical for the development of type I diabetes in the NOD mouse. Proc Natl Acad Sci USA, 105(37), 14028-14033.
Stechova K, Bohmova K, Vrabelova Z, Sepa A, Stadlerova G, Zacharovova K, Faresjö M, 2007: High T-helper-1 cytokines but low T-helper-3 cytokines, inflammatory cytokines and chemokines in children with high risk of developing type 1 diabetes. Diabetes Metab Res Rev, 23(6), 462-471.
Stephens JM, Lee J, Pilch PF, 1997: Tumor necrosis factor-alpha-induced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor substrate-1 and GLUT4 expression without a loss of insulin receptor-mediated signal transduction. J Biol Chem, 272(2), 971-976.
Stith RD, Luo J, 1994: Endocrine and carbohydrate responses to interleukin-6 in vivo. Circ Shock, 44(4):210-215.
Straczkowski M, Dzienis-Straczkowska S, Stêpieñ A, Kowalska I, Szelachowska M, Kinalska I, 2002: Plasma interleukin-8 concentrations are increased in obese subjects and related to fat mass and tumor necrosis factor-alpha system. J Clin Endocrinol Metab, 87(10), 4602-4606.
Straczkowski M, Kowalska I, Nikolajuk A, Krukowska A, Gorska M, 2005: Plasma interleukin-10 concentration is positively related to insulin sensitivity in young healthy individuals. Diabetes Care, 28(8), 2036-2037.
Straczkowski M, Kowalska I, Nikolajuk A, Otziomek E, Adamska A, Karolczuk-Zarachowicz M, Gorska M, 2007: Increased serum interleukin-18 concentration is associated with hypoadiponectinemia in obesity, independently of insulin resistance. Int J Obes (Lond), 31(2), 221-225.
Suárez-Álvarez K, Solís-Lozano L, Leon-Cabrera S, González-Chávez A, Gómez-Hernández G, Quiñones- Álvarez MS, Serralde-Zúñiga AE, Hernández-Ruiz J, Ramírez-Velásquez J, Galindo-González FJ, ZavalaCastillo JC, De León-Nava MA, Robles-Díaz G,Escobedo G, 2013: Serum IL-12 is increased in Mexican obese subjects and associated with lowgrade inflammation and obesity-related parameters. Mediators Inflamm, 2013, 967067.
Suk K, Kim S, Kim YH, Kim KA, Chang I, Yagita H, Shong M, Lee MS, 2001: IFN-gamma/TNF-alpha synergism as the final effector in autoimmune diabetes: a key role for STAT1/IFN regulatory factor-1 pathway in pancreatic beta cell death. J Immunol, 166(7), 4481- 4489.
Sung KC, Rhee EJ, Ryu S, Kim BJ, Kim BS, Lee WY, Oh KW, Kim YB, Chung PW, Kim H, Byrne CD, Lee KB, Park SW, 2015: Increased Cardiovascular Mortality in Subjects With Metabolic Syndrome Is Largely Attributable to Diabetes and Hypertension in 159,971 Korean Adults. J Clin Endocrinol Metab, 100(7), 2606-2612.
Sutherland AP, Van Belle T, Wurster AL, Suto A, Michaud M, Zhang D, Grusby MJ, von Herrath M, 2009: Interleukin-21 is required for the development of type 1 diabetes in NOD mice. Diabetes, 58(5), 1144- 1155.
Temaru R, Urakaze M, Satou A, Yamazaki K, Nakamura N, Kobayashi M, 1997: High glucose enhances the gene expression of interleukin-8 in human endothelial cells, but not in smooth muscle cells: possible role of interleukin-8 in diabetic macroangiopathy. Diabetologia, 40(5):610-613.
Terkeltaub R, Boisvert WA, Curtiss LK, 1998: Chemokines and atherosclerosis. Curr Opin Lipidol, 9(5), 397-405.
Trinchieri G, 1995: Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol, 13, 251-276.
Tsigos C, Papanicolaou DA, Kyrou I, Defensor R, Mitsiadis CS, Chrousos GP, 1997: Dose-dependent effects of recombinant human interleukin-6 on glucose regulation. J Clin Endocrinol Metab, 82(12), 4167- 4170.
Uyemura K, Demer LL, Castle SC, Jullien D, Berliner JA, Gately MK, Warrier RR, Pham N, Fogelman AM, Modlin RL, 1996: Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J Clin Invest, 97(9), 2130-2138.
Van de Velde H, Janssens GP, de Rooster H, Polis I, Peters I, Ducatelle R, Nguyen P, Buyse J, Rochus K, Xu J, Verbrugghe A, Hesta M, 2013: The cat as a model for human obesity: insights into depotspecific inflammation associated with feline obesity. Br J Nutr, 110(7), 1326-1335.
Van Exel E, Gussekloo J, de Craen AJ, Frölich M, Bootsma-Van Der Wiel A, Westendorp RG; Leiden 85 Plus Study, 2002: Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 diabetes : the Leiden 85-Plus Study. Diabetes, 51(4), 1088-1092.
Vick MM, Adams AA, Murphy BA, Sessions DR, Horohov DW, Cook RF, Shelton BJ, Fitzgerald BP, 2007: Relationships among inflammatory cytokines, obesity, and insulin sensitivity in the horse. J Anim Sci, 85(5), 1144-1155.
Wachlin G, Augstein P, Schröder D, Kuttler B, Klöting I, Heinke P, Schmidt S, 2003: IL-1beta, IFN-gamma and TNF-alpha increase vulnerability of pancreatic beta cells to autoimmune destruction. J Autoimmun, 20(4), 303-312.
Wada T, Hoshino M, Kimura Y, Ojima M, Nakano T, Koya D, Tsuneki H, Sasaoka T, 2011: Both type I and II IFN induce insulin resistance by inducing different isoforms of SOCS expression in 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab, 300(6), E1112-1123.
Wegner M, Winiarska H, Bobkiewicz-Kozłowska T, Dworacka M, 2008: IL-12 serum levels in patients with type 2 diabetes treated with sulphonylureas. Cytokine, 42(3), 312-316.
Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr, 2003: Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest, 112(12), 1796-1808.
Wen Y, Gu J, Li SL, Reddy MA, Natarajan R, Nadler JL, 2006: Elevated glucose and diabetes promote interleukin-12 cytokine gene expression in mouse macrophages. Endocrinology, 147(5), 2518-2525.
Winkler G, Dworak O, Salamon F, Salamon D, Speer G, Cseh K, 1998: Increased interleukin-12 plasma concentrations in both, insulin-dependent and noninsulin-dependent diabetes mellitus. Diabetologia, 41(4), 488.
Wong N, Fam BC, Cempako GR, Steinberg GR, Walder K, Kay TW, Proietto J, Andrikopoulos S, 2011: Deficiency in interferon-gamma results in reduced body weight and better glucose tolerance in mice. Endocrinology, 152(10), 3690-3699.
Wood IS, Wang B, Trayhurn P, 2009: IL-33, a recently identified interleukin-1 gene family member, is expressed in human adipocytes. Biochem Biophys Res Commun, 384(1), 105-109.
Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H, 2003: Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest, 112(12), 1821-1830.
Yamakawa T, Tanaka S, Yamakawa Y, Kiuchi Y, Isoda F, Kawamoto S, Okuda K, Sekihara H, 1995: Augmented production of tumor necrosis factoralpha in obese mice. Clin Immunol Immunopathol, 75(1), 51-56.
Yue TL, Mckenna PJ, Gu JL, Feuerstein GZ, 1993: Interleukin-8 is chemotactic for vascular smooth muscle cells. Eur J Pharmacol, 240(1), 81-84.
Zachurzok-Buczyńska A, Klimek K, Firek-Pedras M, Małecka-Tendera E, 2011: Are metabolic syndrome and its components in obese children influenced by the overweight status or the insulin resistance? Endokrynol Pol, 62(2), 102-108.
Zeyda M, Wernly B, Demyanets S, Kaun C, Hämmerle M, Hantusch B, Schranz M, Neuhofer A, Itariu BK, Keck M, Prager G, Wojta J, Stulnig TM, 2013: Severe obesity increases adipose tissue expression of interleukin-33 and its receptor ST2, both predominantly detectable in endothelial cells of human adipose tissue. Int J Obes, 37(5), 658-665.
Zhang YF, Yang YS, Hong J, Gu WQ, Shen CF, Xu M, Du PF, Li XY, Ning G, 2006: Elevated serum levels of interleukin-18 are associated with insulin resistance in women with polycystic ovary syndrome. Endocrine, 29(3), 419-423.
Zoran DL, 2010: Obesity in dogs and cats: a metabolic and endocrine disorder. Vet Clin North Am, 40, 221- 239.
Zozuliñska D, Majchrzak A, Sobieska M, Wiktorowicz K, Wierusz-Wysocka B, 1999: Serum interleukin-8 level is increased in diabetic patients. Diabetologia, 42(1), 117-118.

APA	Yarim G, Kazak F (2016). Metabolik Sendrom ve Bileşenlerinde Sitokin Yanıtı. , 90 - 99.
Chicago	Yarim Gul Fatma,Kazak Filiz Metabolik Sendrom ve Bileşenlerinde Sitokin Yanıtı. (2016): 90 - 99.
MLA	Yarim Gul Fatma,Kazak Filiz Metabolik Sendrom ve Bileşenlerinde Sitokin Yanıtı. , 2016, ss.90 - 99.
AMA	Yarim G,Kazak F Metabolik Sendrom ve Bileşenlerinde Sitokin Yanıtı. . 2016; 90 - 99.
Vancouver	Yarim G,Kazak F Metabolik Sendrom ve Bileşenlerinde Sitokin Yanıtı. . 2016; 90 - 99.
IEEE	Yarim G,Kazak F "Metabolik Sendrom ve Bileşenlerinde Sitokin Yanıtı." , ss.90 - 99, 2016.
ISNAD	Yarim, Gul Fatma - Kazak, Filiz. "Metabolik Sendrom ve Bileşenlerinde Sitokin Yanıtı". (2016), 90-99.

APA	Yarim G, Kazak F (2016). Metabolik Sendrom ve Bileşenlerinde Sitokin Yanıtı. Harran Üniversitesi Veteriner Fakültesi Dergisi, 5(1), 90 - 99.
Chicago	Yarim Gul Fatma,Kazak Filiz Metabolik Sendrom ve Bileşenlerinde Sitokin Yanıtı. Harran Üniversitesi Veteriner Fakültesi Dergisi 5, no.1 (2016): 90 - 99.
MLA	Yarim Gul Fatma,Kazak Filiz Metabolik Sendrom ve Bileşenlerinde Sitokin Yanıtı. Harran Üniversitesi Veteriner Fakültesi Dergisi, vol.5, no.1, 2016, ss.90 - 99.
AMA	Yarim G,Kazak F Metabolik Sendrom ve Bileşenlerinde Sitokin Yanıtı. Harran Üniversitesi Veteriner Fakültesi Dergisi. 2016; 5(1): 90 - 99.
Vancouver	Yarim G,Kazak F Metabolik Sendrom ve Bileşenlerinde Sitokin Yanıtı. Harran Üniversitesi Veteriner Fakültesi Dergisi. 2016; 5(1): 90 - 99.
IEEE	Yarim G,Kazak F "Metabolik Sendrom ve Bileşenlerinde Sitokin Yanıtı." Harran Üniversitesi Veteriner Fakültesi Dergisi, 5, ss.90 - 99, 2016.
ISNAD	Yarim, Gul Fatma - Kazak, Filiz. "Metabolik Sendrom ve Bileşenlerinde Sitokin Yanıtı". Harran Üniversitesi Veteriner Fakültesi Dergisi 5/1 (2016), 90-99.